AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02252640 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)
Study NCT02252640 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)
Study NCT02252640 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP (5 x 10^10 vp)
Study NCT02252640 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP (2 x 10^8 pfu)
Study NCT01430143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Daily exercise for 12 weeks.
Study NCT00906178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CyberSenga
Description: Internet-based HIV prevention program
Study NCT02501148 — intervention group
Intervention type: DEVICE
Intervention: carotid artery stenting
Description: Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
Study NCT01721486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
Study NCT01721486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO acetaminophen
Description: PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
Study NCT01178476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyposafe Hypoglycaemia alarm device
Description: An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
Study NCT01178476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyposafe Hypoglycaemia alarm device
Description: An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
Study NCT02030769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pronase
Description: use pronase to improve visibility during endoscopical iodine staining
Study NCT04078529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Assessment
Description: Use of the Homefast assessment tool to reduce risk of falls at home.
Study NCT02030769 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
Study NCT03926949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
Study NCT03926949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Nutrition Care
Description: Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
Study NCT00582712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
Study NCT01501890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroxyprogesterone caproate
Description: 250mg once a week by intramuscular administration
Study NCT01501890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study NCT01693497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogical exposure therapy
Description: This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
Study NCT01465880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part A
Description: Smoking abstinence, smoking 2 and 4 cigarettes
Study NCT03700840 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interdental brushes
Description: interdental brush at 4 sites and PCR analysis
Study NCT00263432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human allogenic chondrocytes
Description: Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
Study NCT03583359 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiesse (+)
Description: Radiesse (+) for jawlines.
Study NCT03583359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse (+)
Description: Radiesse (+) for jawlines.
Study NCT01415583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 0.5mg/kg (max dose 20mg)
Study NCT01415583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 0.5mg/kg (max dose 20mg)
Study NCT02764359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV vancomycin
Description: IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
Study NCT01027559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
Study NCT01027559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
Study NCT01970241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: NPH given per study table based on steroid dose and patient weight in kg.
Study NCT01970241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Correction Factor
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
Study NCT01970241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Correction Factor
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
Study NCT04700085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMotion Knee
Description: The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
Study NCT02672189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVA-Online
Description: Internet-based cognitive behavioral therapy
Study NCT02874534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Treatment
Description: Treatment will consist of 15 weekly 45-minute sessions.
Study NCT04175899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Oral Chemo Care Program (POCCP)
Description: Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients.
Study NCT00829634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: l-methamphetamine
Description: 5mg of l-methamphetamine per day throughout the 2 week study
Study NCT00829634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: d-methamphetamine
Description: 15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 14 mg
Description: 1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 14 mg
Description: 1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 28 mg
Description: 1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT02036580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tralokinumab cohort 1
Description: Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Study NCT02036580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tralokinumab cohort 2
Description: Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Study NCT02036580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02149355 — intervention group
Intervention type: OTHER
Intervention: teeth molding
Description: teeth molding in patients suffering from congenital fourth nerve palsy
Study NCT00452075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT01693497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (German Adaptation)
Description: This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
Study NCT04812782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
Study NCT04812782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
Study NCT02959294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
Study NCT02959294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
Study NCT02959294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV deployment AD-cSVF
Description: Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
Study NCT03141125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physalis angulata ethanol extract
Description: Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
Study NCT03141125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active component at the same dosage of 3x250 mg/day given orally for 3 months
Study NCT02478632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects do not receive study medication in this study 202094
Description: Participants do not receive study medication in this study 202094.
Study NCT00287001 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cold air cooling
Study NCT02108756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-pantoprazole sodium
Description: 2 injection L-pantoprazole sodium (40mg), Bid
Study NCT02108756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panmeilu
Description: An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
Study NCT01602601 — intervention group
Intervention type: DRUG
Intervention: Idursulfase
Description: recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
Study NCT01602601 — intervention group
Intervention type: DRUG
Intervention: GSK2788723
Description: GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
Study NCT02136004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closer VSS
Description: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
Study NCT04115774 — intervention group
Intervention type: DRUG
Intervention: bisphosphonates
Description: Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
Study NCT01258556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with L. rhamnosus fiti
Description: 200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
Study NCT01258556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt not supplemented with a probiotic strain.
Description: 200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
Study NCT01539070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating and physical activity counseling
Description: The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity.
Study NCT01281384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Imaging
Study NCT01281384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Imaging
Study NCT04053972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral lenvatinib after hepatectomy
Study NCT04875455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation
Description: In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
Study NCT02998671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Study NCT02998671 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CJM112
Study NCT02998671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02038946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02272036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy is performed in both study arm as standard examination
Study NCT02272036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone
Description: SMS received by mobile phone
Study NCT03098433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Single dose
Study NCT03098433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Active comparator
Study NCT03098433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT01667133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib - Phase 1
Description: 30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
Study NCT01667133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib - Phase 2
Description: Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
Study NCT04397367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
Study NCT04397367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg twice a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
Study NCT04397367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg once a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
Study NCT04397367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 2.5 mg once a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
Study NCT04173286 — intervention group
Intervention type: PROCEDURE
Intervention: antibiotherapy
Description: \< 7 days
Study NCT01331746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD515
Description: 20 mg oromucosal-oral administration qds for 7 days
Study NCT01331746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: qds for 7 days
Study NCT02720523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral